HC Wainwright Forecasts Opus Genetics Q1 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Opus Genetics in a report issued on Thursday, November 13th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.09) for the quarter. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.09) EPS.

Several other analysts have also commented on IRD. Wedbush began coverage on shares of Opus Genetics in a research report on Wednesday, October 29th. They set an “outperform” rating and a $8.00 price target on the stock. Wall Street Zen lowered Opus Genetics from a “hold” rating to a “sell” rating in a research note on Saturday. Chardan Capital reissued a “buy” rating and set a $9.00 price objective on shares of Opus Genetics in a research report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.80.

Opus Genetics Price Performance

Shares of IRD stock opened at $1.88 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.90 and a quick ratio of 1.90. The company has a market capitalization of $122.21 million, a PE ratio of -0.98 and a beta of 0.16. The firm’s 50-day moving average is $1.83 and its two-hundred day moving average is $1.33. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $2.37.

Opus Genetics (NASDAQ:IRD) last issued its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $3.08 million during the quarter, compared to the consensus estimate of $3.07 million. Opus Genetics had a negative return on equity of 384.33% and a negative net margin of 377.89%.

Institutional Trading of Opus Genetics

Several hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. raised its holdings in Opus Genetics by 95.6% in the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after acquiring an additional 11,000 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Opus Genetics in the first quarter worth approximately $26,000. Apollon Wealth Management LLC purchased a new stake in Opus Genetics in the first quarter valued at approximately $28,000. Comerica Bank purchased a new stake in Opus Genetics in the first quarter valued at approximately $29,000. Finally, Kestra Private Wealth Services LLC acquired a new position in Opus Genetics during the first quarter worth approximately $47,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.